Relmada Therapeutics

Relmada appoints Bipin Dalmia as chief business officer; he will lead corporate strategy, commercial planning and business development and report to CEO Sergio Traversa. Dalmia brings nearly 30 years of experience, most recently 14 years at Ferring Pharmaceuticals, where he was responsible for uro-oncology and the launch and lifecycle strategy for ADSTILADRIN and completed more than 20 strategic transactions. Relmada is developing, among other programs, the intravesical therapy NDV-01 for non-muscle-invasive bladder cancer and Sepranolon for CNS disorders. » More on de.investing.com

Relmada Therapeutics has named Dr. Michael Quirk senior advisor for its sepranolon program. Quirk has more than 20 years of experience in the discovery and development of neuroscience drugs, most recently serving as chief scientific officer at Sage Therapeutics. Sepranolon, a synthetic isoallopregnanolone, targets disorders with excessive GABAergic activity such as Prader‑Willi syndrome, Tourette’s and obsessive‑compulsive disorders; more than 335 patients have been treated in studies to date. The clinical biotech is valued at about $669 million, has seen a 732% stock increase in 2025, and, according to filings, shows a strong short‑term liquidity position. » More on de.investing.com

Relmada Therapeutics will participate in the Jefferies Global Healthcare Conference in New York from June 2–4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will hold a fireside chat on June 4 at 12:50 p.m. ET, which will be webcast, and company management will be available for one‑on‑one meetings with investors. The webcast recording will be available for 90 days after the presentation. Relmada is a clinical-stage biotechnology company with the Phase II candidates NDV‑01 and Sepranolon; the stock rose 901% over the past year. » More on de.investing.com

Relmada Therapeutics reported Q4 2025 EPS of -$0.27, missing the consensus estimate of -$0.17. Despite the negative surprise, the stock rose slightly by 0.64% in premarket trading. The company has $93 million in cash and has secured additional financing, which should support operations through 2029. Promising clinical data for NDV-01 underpin the long-term growth potential, while cost control and operating cash burn are cited as risks. » More on de.investing.com

Relmada Therapeutics announced at the Leerink Global a strategic shift to uro-oncology and put NDV-01 for bladder cancer at the center. NDV-01 showed complete response rates of 76% in high‑risk NMIBC and 80% in BCG‑unresponsive patients; a rescue study with 87 patients is set to begin midyear, with initial three‑month data expected by the end of 2026. The drug can be administered in five minutes, which could enable wider use outside academic centers. Relmada raised $160 million at $4.75 per share and is seeking approval as a second‑line therapy for BCG‑unresponsive patients. » More on de.investing.com